Chen VL, et al. - Given that hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide, researchers tried to explore the real-world impacts of anti-viral therapy on survival after HCC diagnosis. This international multicenter cohort study was conducted on 2,518 HBV-related HCC cases diagnosed between 2000 and 2015. They utilized Cox proportional hazards models to estimate hazard ratios for anti-viral therapy and cirrhosis on the risk of death. Findings revealed that, in patients with HBV-related HCC, anti-viral therapy improved overall survival across cancer stages and treatment types, however, it was underutilized at both US and Asia centers. They suggested that expanded use of anti-viral therapy in HBV-related HCC and better links to care for HBV patients were required.